<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF0E4E02-73BE-44CF-8C00-2CEDF7E3C89B"><gtr:id>FF0E4E02-73BE-44CF-8C00-2CEDF7E3C89B</gtr:id><gtr:name>University of South Florida</gtr:name><gtr:address><gtr:line1>4202 East Fowler Avenue</gtr:line1><gtr:postCode>33620</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF0E4E02-73BE-44CF-8C00-2CEDF7E3C89B"><gtr:id>FF0E4E02-73BE-44CF-8C00-2CEDF7E3C89B</gtr:id><gtr:name>University of South Florida</gtr:name><gtr:address><gtr:line1>4202 East Fowler Avenue</gtr:line1><gtr:postCode>33620</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E7CF1C00-6496-4E6F-A64E-CD46D9C74470"><gtr:id>E7CF1C00-6496-4E6F-A64E-CD46D9C74470</gtr:id><gtr:firstName>Deb</gtr:firstName><gtr:otherNames>Ann</gtr:otherNames><gtr:surname>Hall</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_14094"><gtr:id>FA929562-B8DE-4A2A-9D6D-A0BD0455DCD3</gtr:id><gtr:title>Biomedical Catalyst ? Clinical proof of concept trial of a Kv3 modulator for the treatment of tinnitus</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MC_PC_14094</gtr:grantReference><gtr:abstractText>Tinnitus is a chronic, under-recognised condition that affects over 10% of adults, causing significant suffering. There are no approved drugs and current treatments, such as counselling, only help patients to cope with symptoms. This project will provide clinical proof-of-concept evaluation of the efficacy of a novel ion channel drug in patients with tinnitus. AUT00063, currently completing Phase I trials, is being developed by Autifony Therapeutics for the treatment of age-related hearing loss; however, there is a strong scientific rationale to suggest potential for the drug to help control tinnitus. Autifony will work in collaboration with leading tinnitus expert, Prof Deborah Hall, Director and Research lead for Tinnitus aetiology and management at the National Institute for Health Research, Nottingham Hearing Biomedical Research Unit, University of Nottingham, on this clinical trial as a major step towards potentially the first effective oral drug to treat tinnitus.</gtr:abstractText><gtr:technicalSummary>The trial is a proof-of-concept Phase II efficacy and safety study of AUT00063 in patients with tinnitus arising from age-related or noise-induced cochlear damage. The trial will evaluate the ability of the drug to alleviate tinnitus, measured using a self-report scale, the Tinnitus Functional Index (TFI, Meikle et al., 2012 Ear Hear 33:153-76), following 4 weeks of treatment. The trial will have a randomised, double-blind, placebo-controlled, 3-arm parallel-group design testing two doses of AUT00063 (400 and 600mg) vs placebo. Secondary objective markers of efficacy will also be used to address scientific and mechanistic questions concerning the nature of tinnitus and the actions of the drug within the central auditory system. These will include measures of tinnitus loudness (Henry et al., 2013 J Rehab Res Dev 50:573-4) and change in electrophysiological correlates at both brainstem and cortical levels (auditory brainstem response, Schaette and McAlpine 2011 J Neurosci 31:13452-57, and resting state EEG, Adjamian et al., 2012 JARO 13:715-31). Historically, the quality of tinnitus trials has been poor (Hoare et al., 2012 JARO 13: 543-59). Our innovative trial design aims to address the weakness of previous tinnitus trials by implementing gold-standard methodologies. Importantly, two interim analyses will be conducted using an Independent Data Management Committee (IDMC) to test for trial futility, and to allow for adaptation of recruitment to favour inclusion of likely responders. i</gtr:technicalSummary><gtr:fund><gtr:end>2016-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>0</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of South Florida</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Communication Sciences &amp; Disorders</gtr:department><gtr:description>Issues in recruiting to phase IIa pharmaceutical trials in ENT and Audiology: An evaluation of the QUIET-1 and CLARITY-1 trials</gtr:description><gtr:id>631C3904-F562-481A-939F-161F43C11EFC</gtr:id><gtr:impact>A publication in under review.</gtr:impact><gtr:outcomeId>58b7124536d495.67711059-1</gtr:outcomeId><gtr:partnerContribution>Experience of conducting the CLARITY-1 trial with Autifony Therapeutics was shared with the UoN team and we identified common challenges and barriers as well as common strengths with respect to recruitment strategies for drug trials in Audiology</gtr:partnerContribution><gtr:piContribution>Experience of conducting the QUIET-1 trial with Autifony Therapeutics was shared with the USF team and we identified common challenges and barriers as well as common strengths with respect to recruitment strategies for drug trials in Audiology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Magazine article for charity</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A0523E3F-BD7B-416A-9E3F-2DD323F65F85</gtr:id><gtr:impact>The short article will appear in an online magazine that is mailed out to all members and stakeholders involved in the UK charity for people with hearing loss and tinnitus (Action on Hearing Loss). The article highlights the Technology Strategy Board bid and the commercial partnership. 'Successful partnerships bring a boost to UK hearing research'

The article is submitted but will not appear until mid-November 2014.</gtr:impact><gtr:outcomeId>545a65b53909e7.13301672</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.actiononhearingloss.org.uk/community/blogs/our-guest-blog/new-funding-boosts-tinnitus-research.aspx</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Magazine article for audiology professionals</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>92DDF30E-5E64-4666-8874-D3B006DF5E41</gtr:id><gtr:impact>Invited article for Audacity - the magazine for members of the British Society of Audiology</gtr:impact><gtr:outcomeId>56ded6fada63e8.07924143</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>This proof-of-concept study has explored the potential of Autifony's lead Kv3 modulator, AUT00063, to reduce the symptoms of tinnitus in people who have subjective tinnitus. Technology Strategy Board funding provides vital support for a phase IIa trial to assess safety and efficacy. A planned interim analysis at the half way point indicated that the intervention did not bring about a clinically meaningful change in symptoms. As a result the Independent Data Monitoring Committee recommended that the trial be closed. The trial was closed in October 2015, with database lock in March 2016.</gtr:description><gtr:id>1FCDAEDF-FA13-4FA3-9C74-3EDA13811944</gtr:id><gtr:impact>Data analysis will be ongoing throughout 2016. However, notable impacts so far relate to developing a better understanding about recruitment strategies for clinical trials in ENT. We anticipate writing this up as a manuscript to facilitate dissemination of good practice in how to conduct a clinical trial.</gtr:impact><gtr:outcomeId>545a66df346bf2.25070138</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>AUT00063</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.autifony.com/autifony-tinnitus-phase-IIa-trial.asp</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>847CD79C-3F2D-4087-BE00-0ED465818D0D</gtr:id><gtr:title>A Balanced Randomised Placebo Controlled Double-Blind Study to Investigate the Efficacy and Safety of AUT00063 versus Placebo in Subjective Tinnitus: Protocol for a Phase IIa Trial</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7cb7ec8803be262815f43b82d3065e5"><gtr:id>b7cb7ec8803be262815f43b82d3065e5</gtr:id><gtr:otherNames>Hall DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>00000000</gtr:issn><gtr:outcomeId>56ded59a897046.80112142</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19DEA7B9-923F-4061-8F47-ACE533B298F4</gtr:id><gtr:title>How to Choose Between Measures of Tinnitus Loudness for Clinical Research? A Report on the Reliability and Validity of an Investigator-Administered Test and a Patient-Reported Measure Using Baseline Data Collected in a Phase IIa Drug Trial.</gtr:title><gtr:parentPublicationTitle>American journal of audiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7cb7ec8803be262815f43b82d3065e5"><gtr:id>b7cb7ec8803be262815f43b82d3065e5</gtr:id><gtr:otherNames>Hall DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1059-0889</gtr:issn><gtr:outcomeId>5a84dd619d40b2.94871419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AEAB570-B2AE-4664-99EF-78D622F9AF7B</gtr:id><gtr:title>A Balanced Randomised Placebo Controlled Double-Blind Study to Investigate the Efficacy and Safety of AUT00063 versus Placebo in Subjective Tinnitus: Protocol for a Phase IIa Trial</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7cb7ec8803be262815f43b82d3065e5"><gtr:id>b7cb7ec8803be262815f43b82d3065e5</gtr:id><gtr:otherNames>Hall DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b70dbac37513.69236864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>901B1A4C-7DC7-45FA-B431-2081A2AF43E0</gtr:id><gtr:title>Autifony QUIET-1 Clinical Trial of AUT00063 for the Treatment of Tinnitus</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70415e9c4377bef81d33867414382298"><gtr:id>70415e9c4377bef81d33867414382298</gtr:id><gtr:otherNames>Large C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b70e7c5151e3.03829980</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FD1FDC3-85B1-47E1-837B-595B457FDD1F</gtr:id><gtr:title>A Place for Everything and Everything in its Place: The Practicalities of randomised clinical trials</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bce87ee15a2fd4dcc9b6ec469f955a8d"><gtr:id>bce87ee15a2fd4dcc9b6ec469f955a8d</gtr:id><gtr:otherNames>Millar B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b710ce40a145.25103708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96996125-13CC-482C-9B6B-0967B3F2E887</gtr:id><gtr:title>Taming the paperwork mountain: The logistics of a randomised clinical trial</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bce87ee15a2fd4dcc9b6ec469f955a8d"><gtr:id>bce87ee15a2fd4dcc9b6ec469f955a8d</gtr:id><gtr:otherNames>Millar B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b70f94418ab4.18078079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EDE6D840-B83D-4280-A62D-2AF9D1679C61</gtr:id><gtr:title>A Balanced Randomised Placebo Controlled Double-Blind Study to Investigate the Efficacy and Safety of AUT00063 versus Placebo in Subjective Tinnitus</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b7cb7ec8803be262815f43b82d3065e5"><gtr:id>b7cb7ec8803be262815f43b82d3065e5</gtr:id><gtr:otherNames>Hall DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b70d1007f449.68704810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>300AB9F8-4816-4D98-9524-299123188174</gtr:id><gtr:title>Recruiting ENT and Audiology patients into pharmaceutical trials: evaluating the multi-centre experience in the UK and USA.</gtr:title><gtr:parentPublicationTitle>International journal of audiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94a387092e3d6d3c51607c1a45bd83a0"><gtr:id>94a387092e3d6d3c51607c1a45bd83a0</gtr:id><gtr:otherNames>Sanchez VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1499-2027</gtr:issn><gtr:outcomeId>5a84db9e2292d0.83211096</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_14094</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>5585DDA6-FCF6-4B64-8332-1BDFE62CE94E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Ear</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>